Americana Partners LLC Purchases Shares of 314 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Americana Partners LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 314 shares of the biopharmaceutical company’s stock, valued at approximately $330,000.

Several other institutional investors have also recently made changes to their positions in the business. Focus Financial Network Inc. boosted its position in shares of Regeneron Pharmaceuticals by 7.4% during the third quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 37 shares during the last quarter. LCM Capital Management Inc lifted its stake in Regeneron Pharmaceuticals by 4.6% in the 3rd quarter. LCM Capital Management Inc now owns 543 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 24 shares in the last quarter. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $37,000. Oak Harvest Investment Services grew its position in shares of Regeneron Pharmaceuticals by 25.6% during the third quarter. Oak Harvest Investment Services now owns 2,779 shares of the biopharmaceutical company’s stock valued at $2,921,000 after purchasing an additional 567 shares in the last quarter. Finally, SteelPeak Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the third quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on REGN shares. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada cut their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $1,090.24.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:REGN opened at $843.60 on Friday. The business’s 50 day moving average is $1,058.43 and its 200 day moving average is $1,039.88. The stock has a market cap of $93.00 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $783.57 and a 52-week high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $8.79 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.